1. Home
  2. RNXT vs BGSF Comparison

RNXT vs BGSF Comparison

Compare RNXT & BGSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNXT
  • BGSF
  • Stock Information
  • Founded
  • RNXT 2012
  • BGSF 2007
  • Country
  • RNXT United States
  • BGSF United States
  • Employees
  • RNXT N/A
  • BGSF N/A
  • Industry
  • RNXT Biotechnology: Pharmaceutical Preparations
  • BGSF Professional Services
  • Sector
  • RNXT Health Care
  • BGSF Consumer Discretionary
  • Exchange
  • RNXT Nasdaq
  • BGSF Nasdaq
  • Market Cap
  • RNXT 44.6M
  • BGSF 49.7M
  • IPO Year
  • RNXT 2021
  • BGSF N/A
  • Fundamental
  • Price
  • RNXT $1.40
  • BGSF $4.41
  • Analyst Decision
  • RNXT Strong Buy
  • BGSF Strong Buy
  • Analyst Count
  • RNXT 2
  • BGSF 1
  • Target Price
  • RNXT $7.00
  • BGSF $9.00
  • AVG Volume (30 Days)
  • RNXT 210.6K
  • BGSF 16.0K
  • Earning Date
  • RNXT 05-15-2025
  • BGSF 05-07-2025
  • Dividend Yield
  • RNXT N/A
  • BGSF N/A
  • EPS Growth
  • RNXT N/A
  • BGSF N/A
  • EPS
  • RNXT N/A
  • BGSF N/A
  • Revenue
  • RNXT $240,000.00
  • BGSF $266,968,000.00
  • Revenue This Year
  • RNXT $3,927.91
  • BGSF $4.29
  • Revenue Next Year
  • RNXT $219.75
  • BGSF N/A
  • P/E Ratio
  • RNXT N/A
  • BGSF N/A
  • Revenue Growth
  • RNXT N/A
  • BGSF N/A
  • 52 Week Low
  • RNXT $0.75
  • BGSF $2.91
  • 52 Week High
  • RNXT $1.69
  • BGSF $9.22
  • Technical
  • Relative Strength Index (RSI)
  • RNXT 78.13
  • BGSF 62.89
  • Support Level
  • RNXT $1.17
  • BGSF $4.18
  • Resistance Level
  • RNXT $1.30
  • BGSF $4.55
  • Average True Range (ATR)
  • RNXT 0.08
  • BGSF 0.23
  • MACD
  • RNXT 0.02
  • BGSF 0.02
  • Stochastic Oscillator
  • RNXT 100.00
  • BGSF 84.14

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.

Share on Social Networks: